Indication: Hematological Malignancies
A Multicenter, Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination with Gilteritinib in Subjects with Relapsed/Refractory Acute Myeloid Leukemia.
Sub-indication: AML with FLT3
Line of Therapy: second line
Principal Investigator: Joseph Maly, M.D.Norton Cancer Institute
Email for more information: Heme-NCIResearch@nortonhealthcare.org